American College

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

Retrieved on: 
Tuesday, April 16, 2024
Patient, DiGeorge syndrome, American College, MYGN, Pregnancy, Test management, Myriad Genetics, Ventricular septal defect, FACMG, MD, Doctor of Philosophy, Genetic testing, Medical genetics, Genetics, DNA, SNP, PPV, Genomics, Medicine, FACOG, Dietary supplement

“This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.

Key Points: 
  • “This is now the second publication—one from Myriad and another from a separate laboratory5—showing exemplary PPV for whole-genome-sequencing-based pcfDNA screening.
  • This study enables greater confidence for providers when they receive positive screening results for 22q11.2 microdeletion.
  • 22q11.2 deletion syndrome (22q11.2DS), often called DiGeorge syndrome, is caused by deletions on chromosome 22 (22q11.2 microdeletions).
  • The American College of Medical Genetics and Genomics recently recommended that 22q11.2DS screening be offered to all pregnant patients.

Biomerica provides update on inFoods® IBS expansion

Retrieved on: 
Monday, April 15, 2024
Irritable bowel syndrome, Pain, University, Mayo Clinic, American College, Hospital, Houston Methodist Hospital, ACG, Abdominal pain, API, GI, Patient, Diet, Physician, Trust, Harvard Medical School, Quality of life, IBS, Pharmaceutical industry

IRVINE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.

Key Points: 
  • - Expansion into new offices within current major groups, including Northeast and Ohio; Expansion into new major group in Texas.
  • - Biomerica in discussions for launch of inFoods IBS with large non-GI physician groups opening new market for the product.
  • IRVINE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.
  • Biomerica remains at the forefront of innovative GI solutions, with the inFoods IBS product exemplifying its dedication to improving patient lives.

The Lee Health Heart Institute Achieves Most Abstract Acceptance at the Annual American College of Cardiology Conference

Retrieved on: 
Monday, April 15, 2024
Cardiomyopathy, American College, Health promotion, ACC, Cardiovascular disease, Woman, Cardiac rehabilitation, Moyamoya disease, Abstract, Cardiology, Death, Research, Patient, Parenting, SGLT2, Physician, Heart failure, Medical device

Advancements in research and technology learned at the annual conference will help Lee Health Heart Institute physicians stay at the forefront of cutting-edge practices, ultimately enhancing patient outcomes and strengthening cardiovascular care in Southwest Florida and beyond.

Key Points: 
  • Advancements in research and technology learned at the annual conference will help Lee Health Heart Institute physicians stay at the forefront of cutting-edge practices, ultimately enhancing patient outcomes and strengthening cardiovascular care in Southwest Florida and beyond.
  • “The Lee Health Heart Institute is not only dedicated to treating cardiovascular disease, but also to finding progressive solutions and advancements to keep the community as heart healthy as possible.
  • Based at HealthPark Medical Center, the Lee Health Heart Institute is the largest heart program in Southwest Florida.
  • To learn more about the Lee Health Heart Institute, please visit www.leehealth.org .

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)

Retrieved on: 
Monday, April 15, 2024
Atlanta Marriott Marquis, Mortality, American College, Conference, Length of stay, American College of Cardiology, BVA, Pharmaceutical industry

Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from across the country to transform cardiovascular care, featuring interactive industry-leading education designed for the MedAxiom membership community.

Key Points: 
  • The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought leaders from across the country to transform cardiovascular care, featuring interactive industry-leading education designed for the MedAxiom membership community.
  • “MedAxiom’s spring conference provides an important opportunity to highlight our BVA diagnostic to cardiovascular leaders and innovators.
  • Our aim is to demonstrate how our unique technology directly tackles issues such as readmissions, mortality, and resource optimization.
  • These healthcare systems acknowledge MedAxiom as a leader in introducing solutions that improve outcomes, lower expenses, and enhance patient well-being,” said Michael Feldschuh, CEO and President of Daxor.

Burke Rehabilitation Hospital Names Scott Edelman as Executive Director

Retrieved on: 
Thursday, May 2, 2024
Hospitals, Philanthropy, Health, Fund Raising, University, General Health, Other Philanthropy, Foundation, Education, American College, News, WCA, Rehabilitation, Health care, Trustee, Research, CPA, Certified Fraud Examiner, Rehabilitation hospital, Healthcare Financial Management Association, Interim, MBA, SUNY, CFE, Accounting, ACHE, Iona University, Growth, Management

Burke Rehabilitation Hospital’s Board of Trustees has named Scott A. Edelman, CPA, MBA, CFE, as Executive Director.

Key Points: 
  • Burke Rehabilitation Hospital’s Board of Trustees has named Scott A. Edelman, CPA, MBA, CFE, as Executive Director.
  • Mr. Edelman has been with Burke Rehabilitation, a leading provider of physical and medical rehabilitation, research and graduate medical education, for more than 25 years.
  • The Board has full confidence in Scott’s ability to propel Burke into its next phase of growth, ensuring the organization remains the gold standard of rehabilitation medicine.”
    During Scott Edelman’s tenure as Interim Executive Director, Burke was named a Top Rehabilitation Hospital by US News & World Report in its 2023-24 rankings.
  • Burke was also recognized as having the lowest rate of readmission in the country for a rehabilitation hospital.

New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged

Retrieved on: 
Thursday, May 2, 2024
Research, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Biotechnology, Managed Care, Health, Science, Stanford University, Mortality, Heart, Fluid, Heart failure, ADHF, American College, Clinical trial, GDMT, AUC, Hospital, Weight loss, Partnership, Area studies, Nursing, Patient, Reprieve, Physician, Acute, Circulatory system, Kaiser Permanente, Hyperkalemia, SDOH, HF, Division, Hypotension, Pharmaceutical industry

Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.

Key Points: 
  • Decongestion remains a central goal of inpatient management, but contemporary decongestion practices and associated weight loss are not well described.
  • In the TREAT-AHF study, the distribution of inpatient body weight change was similar to those reported from ADHERE nearly two decades ago.
  • Reprieve is partnering with industry-leading heart failure researchers and Truveta to understand and advance acute heart failure patient outcomes.
  • The clinical evidence from the TREAT-HF study demonstrates that heart failure decongestion management has not substantially changed in 20 years,” said Mark Pacyna, chief executive officer of Reprieve Cardiovascular.

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Retrieved on: 
Wednesday, May 1, 2024
Health, Consumer, Women, Genetics, Baby, Maternity, Clinical Trials, Biotechnology, Fetus, Nucleic acid thermodynamics, Gamma globulin, Episcopal conference, American College, NTRA, Laboratory, RHD (gene), Anemia, Risk, Pregnancy, Blood, Northwell Health, Quality, Genetic testing, Obstetrics, DNA, SNP, ACOG, ASHG, NIPT, Patient, Human genetics, Society, Physician, Antibody, Panorama, Dietary supplement

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test.
  • This comes at a critical time for the healthcare industry, helping physicians navigate patient care given nationwide shortages of Rho(D) immune globulin therapy (RhIg).
  • Natera’s test can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient, including complex pseudogene and RhD-CE-D hybrid variants.
  • The vast majority of other NIPT laboratories do not offer fetal RhD assessment, which makes it a key differentiator in addition to Natera’s core SNP-based technology.

Real. Trial. Lawyers. Launch New Firm — SCHONBUCH HALLISSY LLP to Open Brentwood Office

Retrieved on: 
Wednesday, May 1, 2024
Legal, Professional Services, LLP, American College, IADC, Legal advice, Woman, Law Committee, Female, History, LACBA, International Association, Corporate lawyer, Federation, Lawyer, FDCC, Multimedia, Lee, Defense, Private investigator

New Brentwood based law firm SCHONBUCH HALLISSY LLP, providing exceptional trial skills, litigation strategy and legal counseling, opens on May 1, 2024.

Key Points: 
  • New Brentwood based law firm SCHONBUCH HALLISSY LLP, providing exceptional trial skills, litigation strategy and legal counseling, opens on May 1, 2024.
  • Located at 11999 San Vicente Boulevard in Brentwood, the firm has additional offices in Westlake Village and Mission Viejo.
  • With a rich history in California spanning decades, Schonbuch Hallissy LLP began in 1982 as Daniels, Baratta & Fine LLP, which became Daniels, Fine, Israel & Schonbuch LLP, and then Daniels, Fine, Israel, Schonbuch & Lebovits LLP.
  • SCHONBUCH HALLISSY LLP is bringing on Laurie Julien, to act as its Managing Director to shepherd the firm into the future.

Nationally Recognized Health Services Researcher and Entrepreneur Dr. Dena Bravata Joins Vivante Health’s Clinical Advisory Board

Retrieved on: 
Thursday, April 11, 2024
Education, Stanford University, Palo Alto, California, State, Castlight Health, American College, American Gastroenterological Association, Hospital, CDC, Internal medicine, Advisory board, White, GI, Patient, Work, Physician, Harvard Medical School, Associate, Massachusetts General Hospital, Nursing

CHICAGO, April 11, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced today the addition of Dr. Dena Bravata to its Clinical Advisory Board.

Key Points: 
  • CHICAGO, April 11, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced today the addition of Dr. Dena Bravata to its Clinical Advisory Board.
  • She joins a growing team of internationally recognized experts and physician leaders committed to advancing GI care.
  • Dr. Bravata is a healthcare entrepreneur, executive, and nationally recognized health services researcher.
  • “Vivante Health’s dedication to clinical rigor and use of technology-enabled services in the thoughtful care of patients with digestive health issues excites me,” said Dr. Bravata.

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 10, 2024
Abele, AAAAI, FDA, Citizenship, Research, Healthcare Improvement Scotland, Trial of the century, SMC, IND, Record, Intellectual property, National Congress, American Academy, Attack, Food, ACAAI, Conference, Hereditary angioedema, MHRA, HAE, Therapy, Network, EOP, Book, PRO, Chemistry, CMC, G&A, Investigational New Drug, Doctor of Philosophy, Medication, Research and development, American College, Mass meeting, Health care, Administration, Bank statement, Annual general meeting, Heredity, Pharmaceutical industry

Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.

Key Points: 
  • Pharvaris is currently enrolling in RAPIDe-3, a global pivotal Phase 3 study of deucrictibant immediate-release capsule (PHVS416) for the on-demand treatment of HAE attacks.
  • Effective April 15, 2024, David Nassif, J.D., will join Pharvaris as Chief Financial Officer and will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations.
  • Loss for the fourth quarter of 2023 was €32.7 million, resulting in basic and diluted loss per share of €0.74.
  • Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.